Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Decline in Short Interest

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 9,650,000 shares, a drop of 16.3% from the January 31st total of 11,530,000 shares. Currently, 7.7% of the company's shares are sold short. Based on an average daily volume of 1,270,000 shares, the short-interest ratio is presently 7.6 days.

Institutional Trading of Lyell Immunopharma

Several institutional investors and hedge funds have recently modified their holdings of the stock. Public Employees Retirement System of Ohio bought a new stake in shares of Lyell Immunopharma during the fourth quarter valued at approximately $64,000. venBio Partners LLC bought a new stake in shares of Lyell Immunopharma during the fourth quarter valued at approximately $4,545,000. Two Sigma Advisers LP increased its holdings in Lyell Immunopharma by 143.8% during the fourth quarter. Two Sigma Advisers LP now owns 306,400 shares of the company's stock valued at $196,000 after buying an additional 180,700 shares during the period. Millennium Management LLC increased its holdings in Lyell Immunopharma by 34.8% during the fourth quarter. Millennium Management LLC now owns 957,507 shares of the company's stock valued at $613,000 after buying an additional 247,440 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Lyell Immunopharma by 13.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company's stock valued at $197,000 after buying an additional 36,555 shares during the period. Institutional investors own 66.05% of the company's stock.

Remove Ads

Lyell Immunopharma Trading Up 2.3 %

Shares of Lyell Immunopharma stock traded up $0.02 on Friday, hitting $0.74. 922,983 shares of the company traded hands, compared to its average volume of 1,087,709. The stock's 50 day moving average price is $0.63 and its 200-day moving average price is $0.94. Lyell Immunopharma has a 52 week low of $0.51 and a 52 week high of $3.15. The company has a market cap of $217.13 million, a PE ratio of -0.94 and a beta of -0.41.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.